Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia.
JAMA. 2011 Feb 23;305(8):790-9. doi: 10.1001/jama.2011.188.
Women with a personal history of breast cancer (PHBC) are at risk of developing another breast cancer and are recommended for screening mammography. Few high-quality data exist on screening performance in PHBC women.
To examine the accuracy and outcomes of mammography screening in PHBC women relative to screening of similar women without PHBC.
Cohort of PHBC women, mammogram matched to non-PHBC women, screened through facilities (1996-2007) affiliated with the Breast Cancer Surveillance Consortium.
There were 58,870 screening mammograms in 19,078 women with a history of early-stage (in situ or stage I-II invasive) breast cancer and 58,870 matched (breast density, age group, mammography year, and registry) screening mammograms in 55,315 non-PHBC women.
Mammography accuracy based on final assessment, cancer detection rate, interval cancer rate, and stage at diagnosis.
Within 1 year after screening, 655 cancers were observed in PHBC women (499 invasive, 156 in situ) and 342 cancers (285 invasive, 57 in situ) in non-PHBC women. Screening accuracy and outcomes in PHBC relative to non-PHBC women were cancer rates of 10.5 per 1000 screens (95% CI, 9.7-11.3) vs 5.8 per 1000 screens (95% CI, 5.2-6.4), cancer detection rate of 6.8 per 1000 screens (95% CI, 6.2-7.5) vs 4.4 per 1000 screens (95% CI, 3.9-5.0), interval cancer rate of 3.6 per 1000 screens (95% CI, 3.2-4.1) vs 1.4 per 1000 screens (95% CI, 1.1-1.7), sensitivity 65.4% (95% CI, 61.5%-69.0%) vs 76.5% (95% CI, 71.7%-80.7%), specificity 98.3% (95% CI, 98.2%-98.4%) vs 99.0% (95% CI, 98.9%-99.1%), abnormal mammogram results in 2.3% (95% CI, 2.2%-2.5%) vs 1.4% (95% CI, 1.3%-1.5%) (all comparisons P < .001). Screening sensitivity in PHBC women was higher for detection of in situ cancer (78.7%; 95% CI, 71.4%-84.5%) than invasive cancer (61.1%; 95% CI, 56.6%-65.4%), P < .001; lower in the initial 5 years (60.2%; 95% CI, 54.7%-65.5%) than after 5 years from first cancer (70.8%; 95% CI, 65.4%-75.6%), P = .006; and was similar for detection of ipsilateral cancer (66.3%; 95% CI, 60.3%-71.8%) and contralateral cancer (66.1%; 95% CI, 60.9%-70.9%), P = .96. Screen-detected and interval cancers in women with and without PHBC were predominantly early stage.
Mammography screening in PHBC women detects early-stage second breast cancers but has lower sensitivity and higher interval cancer rate, despite more evaluation and higher underlying cancer rate, relative to that in non-PHBC women.
有乳腺癌病史(PHBC)的女性有罹患另一种乳腺癌的风险,建议进行筛查性乳房 X 光检查。目前,关于 PHBC 女性的筛查表现,仅有少量高质量数据。
与没有 PHBC 的相似女性的筛查相比,检查 PHBC 女性乳房 X 光筛查的准确性和结果。
PHBC 女性队列,与非 PHBC 女性相匹配的乳房 X 光检查,通过设施进行筛查(1996-2007 年),这些设施隶属于乳腺癌监测联合会。
在有早期(原位或 I 期- II 期浸润性)乳腺癌病史的 19078 名女性中,有 58870 次筛查性乳房 X 光检查,在 55315 名非 PHBC 女性中,有 58870 次匹配(乳房密度、年龄组、乳房 X 光检查年份和登记处)筛查性乳房 X 光检查。
基于最终评估的乳房 X 光检查准确性、癌症检出率、间隔期癌症率和诊断时的分期。
在筛查后 1 年内,PHBC 女性中观察到 655 例癌症(499 例浸润性,156 例原位),非 PHBC 女性中观察到 342 例癌症(285 例浸润性,57 例原位)。与非 PHBC 女性相比,PHBC 女性的筛查准确性和结果为:癌症发生率为每 1000 例 10.5(95% CI,9.7-11.3)vs 每 1000 例 5.8(95% CI,5.2-6.4),癌症检出率为每 1000 例 6.8(95% CI,6.2-7.5)vs 每 1000 例 4.4(95% CI,3.9-5.0),间隔期癌症发生率为每 1000 例 3.6(95% CI,3.2-4.1)vs 每 1000 例 1.4(95% CI,1.1-1.7),灵敏度为 65.4%(95% CI,61.5%-69.0%)vs 76.5%(95% CI,71.7%-80.7%),特异性为 98.3%(95% CI,98.2%-98.4%)vs 99.0%(95% CI,98.9%-99.1%),异常乳房 X 光检查结果的比例为 2.3%(95% CI,2.2%-2.5%)vs 1.4%(95% CI,1.3%-1.5%)(所有比较 P<.001)。PHBC 女性中,原位癌的检出灵敏度(78.7%;95% CI,71.4%-84.5%)高于浸润性癌(61.1%;95% CI,56.6%-65.4%),P<.001;与首次癌症发生后的 5 年后(70.8%;95% CI,65.4%-75.6%)相比,初始 5 年内的灵敏度(60.2%;95% CI,54.7%-65.5%)较低,P=0.006;同侧癌(66.3%;95% CI,60.3%-71.8%)和对侧癌(66.1%;95% CI,60.9%-70.9%)的检出灵敏度相似,P=0.96。有和没有 PHBC 的女性的筛查检出和间隔期癌症主要为早期阶段。
尽管 PHBC 女性的评估更多,且潜在癌症发病率更高,但与非 PHBC 女性相比,乳房 X 光筛查可检出早期第二乳腺癌,但敏感性较低,间隔期癌症发生率较高。